TY - JOUR
T1 - The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma
AU - Fiala, Mark A.
AU - Foley, Nicole C.
AU - Zweegman, Sonja
AU - Vij, Ravi
AU - Wildes, Tanya M.
N1 - Funding Information:
This research was made possible by Grant Number K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
Funding Information:
T. Wildes has received research funding from Jannsen. The other authors have no relevant conflicts of interest.
Funding Information:
This research was made possible by Grant Number K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The Center for Administrative Data Research is supported in part by the Washington University Institute of Clinical and Translational Sciences, United States grant UL1 TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), and Grant Number R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, Centers for Medicare & Medicaid Services; Information Management Services Inc.; and the SEER program tumor registries in the creation of the SEER-Medicare database.
Publisher Copyright:
© 2020
PY - 2020/11
Y1 - 2020/11
N2 - Objectives: Tremendous progress has been made in the treatment of multiple myeloma; however, the majority of this success has been demonstrated in younger patients. With 36% of patients >80 years-old at diagnosis, it is important to understand if older patients are receiving similar benefits. Materials and methods: We identified 2155 patients diagnosed with myeloma at age 80 or older in the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare database from 2007 to 2013. A cohort of 2933 similar patients diagnosed with myeloma at age 70–79 was used for comparison using a difference-in-differences design. Results: Only 51% of patients >80 years-old at diagnosis received systemic anti-myeloma treatment. Treatment was associated with a 26% decrease in hazard for death, independent of age, race, gender, poverty, comorbidities, and proxy measures of performance status. In the 70–79 cohort, treatment was associated with a 22% decrease in hazard for death. Based on the difference-in-differences design, there is no statistically significant difference in treatment benefit based on age cohort (p = .610). Conclusions: Anti-myeloma treatment produces a similar survival benefit among the oldest patients. The population over 80, when myeloma incidence peaks, is projected to triple over the next few decades. It is imperative that we continue to advance our understanding of the needs of this vulnerable subgroup of patients with myeloma.
AB - Objectives: Tremendous progress has been made in the treatment of multiple myeloma; however, the majority of this success has been demonstrated in younger patients. With 36% of patients >80 years-old at diagnosis, it is important to understand if older patients are receiving similar benefits. Materials and methods: We identified 2155 patients diagnosed with myeloma at age 80 or older in the Surveillance, Epidemiology, and End Results Program (SEER)-Medicare database from 2007 to 2013. A cohort of 2933 similar patients diagnosed with myeloma at age 70–79 was used for comparison using a difference-in-differences design. Results: Only 51% of patients >80 years-old at diagnosis received systemic anti-myeloma treatment. Treatment was associated with a 26% decrease in hazard for death, independent of age, race, gender, poverty, comorbidities, and proxy measures of performance status. In the 70–79 cohort, treatment was associated with a 22% decrease in hazard for death. Based on the difference-in-differences design, there is no statistically significant difference in treatment benefit based on age cohort (p = .610). Conclusions: Anti-myeloma treatment produces a similar survival benefit among the oldest patients. The population over 80, when myeloma incidence peaks, is projected to triple over the next few decades. It is imperative that we continue to advance our understanding of the needs of this vulnerable subgroup of patients with myeloma.
KW - Multiple myeloma
KW - Novel agents
KW - Older patients
UR - http://www.scopus.com/inward/record.url?scp=85081255150&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2020.03.005
DO - 10.1016/j.jgo.2020.03.005
M3 - Article
C2 - 32169544
AN - SCOPUS:85081255150
SN - 1879-4068
VL - 11
SP - 1274
EP - 1278
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 8
ER -